Copy and paste the "+" delimited list of TIDs into the "Arguments" field of the BTC Company Activity Group page
Revolutionizing cancer therapy on a global basis by developing TCR therapies with the potential to treat a wide range of cancer types and patients.
T Cell and B Cell receptor analysis with Clonoseq.
Adaptive Phage Therapeutics is a clinical-stage company founded to address the challenge of multi-drug resistant pathogenic bacteria.
Addgene is a nonprofit organization dedicated to making it easier for scientists to share plasmids.
Addgene is reaching this goal by operating a plasmid repository for the research ...
Intranasal Porcine Vaccine
Created in 2005, ADDMEDICA is a fast growing European company focused on developing and marketing medical products for: Rare diseases, Serious conditions, Unmet medical needs
Contract tissue-based assays and research
Custom Organic Synthesis
Working on off-the-shelf cellular therapies that may offer the anticancer efficacy of autologous CAR-T treatments without the logistical complexity.
Life Sciences Reagents
Adlai Nortye is a biopharmaceutical company discovering, developing and commercializing new drugs for cancer and metabolic diseases.
ADMA Biologics is a biopharmaceutical company committed to creating superior products for immunodeficient patients at risk for infection.
Admera Health is an advanced molecular diagnostics company focused on personalized medicine and non-invasive cancer testing.
Admittance Technologies, Inc. develops proprietary software and platform technology for heart failure patients. It developed CardioVol, a volume measurement software and platform technology that ...
ADOR Diagnostics is an international IVD company headquartered in Rome, Italy. ADOR develops, manufactures and markets unique in-vitro diagnostic solutions, specially designed for small to mid- ...
AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer ...
Aduro’s three proprietary technology platforms (Live, Attenuated Double-Deleted Listeria (LADD), STING Pathway Activators, and B-select monoclonal antibodies) have the potential to transform the ...